Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.580
-0.040 (-1.10%)
May 15, 2025, 4:00 PM - Market closed
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Corvus Pharmaceuticals stock ranges from a low of $11 to a high of $21. The average analyst price target of $16.33 forecasts a 356.15% increase in the stock price over the next year.
Price Target: $16.33 (+356.15%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $15 → $17 | Buy | Reiterates | $15 → $17 | +374.86% | May 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +318.99% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +207.26% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +207.26% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +207.26% | Jan 2, 2025 |
Financial Forecast
Revenue This Year
n/a
from 101.79M
Revenue Next Year
n/a
EPS This Year
-0.51
from -1.02
EPS Next Year
-0.66
from -0.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 10.5M | 35.9M | ||
| Avg | n/a | 2.6M | 19.9M | ||
| Low | n/a | n/a | 2.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,308.2% | ||
| Avg | - | - | 682.0% | ||
| Low | - | - | -7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | -0.43 | -0.34 | ||
| Avg | -0.51 | -0.66 | -0.65 | ||
| Low | -0.56 | -0.93 | -1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.